Future Financial Wealth Managment LLC Raises Holdings in Johnson & Johnson (NYSE:JNJ)

Future Financial Wealth Managment LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,612 shares of the company’s stock after acquiring an additional 160 shares during the quarter. Future Financial Wealth Managment LLC’s holdings in Johnson & Johnson were worth $571,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Keener Financial Planning LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at approximately $40,000. WFA Asset Management Corp lifted its holdings in shares of Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $44,000. Disciplined Equity Management Inc. acquired a new position in Johnson & Johnson during the 4th quarter valued at about $45,000. Finally, Grayhawk Investment Strategies Inc. raised its stake in Johnson & Johnson by 528.6% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after buying an additional 259 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a report on Monday, June 17th. StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 22nd. Bank of America lowered their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and upped their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Finally, The Goldman Sachs Group began coverage on Johnson & Johnson in a research note on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target on the stock. Eight analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Hold” and an average price target of $174.07.

Johnson & Johnson Stock Down 0.3 %

Johnson & Johnson stock opened at $146.81 on Thursday. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The firm has a market cap of $353.32 billion, a price-to-earnings ratio of 9.15, a price-to-earnings-growth ratio of 2.45 and a beta of 0.53. The business’s 50-day moving average price is $148.13 and its 200 day moving average price is $154.24. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. During the same period in the previous year, the firm earned $2.68 EPS. The business’s quarterly revenue was up 2.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.63 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were paid a dividend of $1.24 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.